Investing.com -- 在美国食品药品监督管理局(FDA)批准该公司的铁蔗糖注射液USP(Iron Sucrose Injection, USP)后,Viatris Inc (NASDAQ:VTRS)股价上涨2.6%,这是Venofer®注射液的首个仿制版本。 这种静脉铁替代产品用于治疗慢性肾病成人和儿科患者的缺铁性贫血。该药物将以三种规格的单剂量小瓶提供:50 mg/2.5mL、...
Source LinkInvesting.com -- 在美国食品药品监督管理局(FDA)批准该公司的铁蔗糖注射液USP(Iron Sucrose Injection, USP)后,Viatris Inc (NASDAQ:VTRS)股价上涨2.6%,这是Venofer®注射液的首个仿制版本。 这种静脉铁替代产品用于治疗慢性肾病成人和儿科患者的缺铁性贫血。该药物将以三种规格的单剂量小瓶提供:50 mg/2.5mL、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.